How to Read “Legal 7-OH Alternative” Claims for Oxonol and MGM-15
“Legal 7-OH alternative” is a dated marketing claim, not a complete product identity. With Oxonol, the manufacturer’s current formula description includes MGM-15—a substance expressly named in DEA’s July 2026 notice of intent.
Four parts every legal claim needs
A useful product-status statement identifies the substance, formula, jurisdiction, and date. Remove any one of those parts and the conclusion can become misleading. A national statement may overlook state law. An old statement may predate a federal notice. A brand-only statement may omit the ingredient named in a regulation.
Why “different from 7-OH” is not the whole answer
MGM-15 is chemically distinct from 7-hydroxymitragynine, but DEA did not limit its July 2026 action to 7-OH. The agency published a companion notice for MGM-15, MGM-16, and mitragynine pseudoindoxyl. Therefore a product can be different from 7-OH and still contain a substance addressed by a related notice.
Brand names versus formulas
The manufacturer describes Oxonol as a brand name for chewable tablets containing MGM-15 and mitragynine. The Federal Register notice does not mention Oxonol; it names MGM-15 and supplies the common chemical name dihydro-7-hydroxymitragynine. The current ingredient panel connects the retail product to the regulatory terminology.
The present federal status
As of July 14, 2026, DEA’s MGM-15 document is a notice of intent. The temporary order is not yet effective. DEA says the order cannot issue before August 5, 2026 and will take effect when published. A current statement should preserve both facts: MGM-15 is expressly targeted, and the later order has not yet taken effect.
What to save when reviewing a claim
- A screenshot or PDF of the product page with the review date.
- The package ingredient panel and lot or batch identifier.
- The exact named compound and any common chemical name.
- The government document, publication date, and effective-status language.
- Applicable state or local guidance.
How MIT differs from an MGM-15 product
MIT means mitragynine, which occurs naturally in the kratom plant. DEA describes MGM-15 as a synthetic derivative produced through chemical modification. An MIT extract concentrates mitragynine and still requires honest percentage, unit, and document disclosures, but it is not another name for MGM-15.
Kratom Paradise MIT pages use that direct identity and do not call the products Oxonol, MGM-15, 7-OH, or therapeutic substitutes. For buyers seeking a simpler ingredient trail, current tablet and powder formats provide a clearer comparison than a broad “alternative” phrase.
Claims that require extra caution
- “Legal everywhere” without a jurisdiction and date.
- “Not covered” because the brand name is absent from a substance-based document.
- “Natural” when a formula includes a derivative that DEA describes as synthetic.
- “FDA approved,” “safe,” or treatment claims without an applicable approval.
- Effect or potency comparisons that are not tied to reliable evidence and the exact formulation.
Use dated primary sources
Read the Federal Register MGM-15 notice and DEA announcement. Use the manufacturer’s Oxonol description only for its account of its own brand and formula. Our living tracker links the current federal documents in one place.
This article is educational product and regulatory information, not medical or legal advice.